Despite ongoing clinical trials and promising results from preclinical studies, the effectiveness of 5-HT6R antagonists as adjunctive therapy in the treatment of Alzheimer’s disease (AD) has not yet been confirmed [16]. Here, HTR6 is linked to Alzheimer disease.